Amicus Therapeutics Inc. (FOLD), which wrapped up 2024 with significant revenue growth, is now setting its sights on achieving sustained double-digit growth in 2025 and beyond.
This global biotechnology company is focused on developing and commercializing novel medicines for rare diseases. It markets Galafold for Fabry disease and Pombiliti + Opfolda, a two-component therapy, to treat late-onset Pompe disease.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com